TFE3 was strongly expressed in the nucleus in the metastatic RCC tissue, and diffused in the cytoplasm in sunitinib sensitive tissue which theoretically consistent with the fact that sunitinib promoted TFE3 translocated into the nucleus by inhibiting VEGF-mTOR signaling pathway (Fig. 1e). Here, MTOR is linked to renal cell carcinoma.